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422Objective: To assess short-term survival after transcatheter mitral valve replacement using a unique mitral valved
stent design and anchoring system.
Methods: The new nitinol self-expandable valved stent houses a trileaflet glutaraldehyde-preserved bioprosthesis
and contains atrial and ventricular fixation systems. Eight pigs underwent transesophageal echocardiogram-
guided transapical mitral valved stent implantation through a lower mini-sternotomy. Intracardiac pressure gra-
dients were estimated by transesophageal echocardiogram.
Results: Themeanmitral annulus sizewas 24.6 1.4mm, and the valved stent sizewas 26.0 2.6mm.The average
mean transvalvular gradient across the valved stent immediately after deployment, at 6 hours, and after 1 week
remained low. The gradient across the neighboring left ventricular outflow tract was not affected. Average animal
survival was 7.3 days (8 hours to 29 days). Animals that died before 1 week (n ¼ 4) were found at necropsy to
have valved stent malpositioning. Animals that survived 1 week or more had accurate deployment and only trace
post-deployment paravalvular leak. The causes of death in this latter group were endocarditis (n¼ 1), failure of atrial
fixation (n¼ 2), and failure of ventricular fixation (n¼ 1). Therewas novalved stent embolization in anyof the animals.
Conclusion: Adequate function and effective anchoring of the new mitral valved stent allowed for short-term
animal survival after transapical mitral valved stent implantation. (J Thorac Cardiovasc Surg 2010;140:422-6)Supplemental material is available online.Video clip is available online.Percutaneous mitral valve repair techniques have been de-
veloped in an attempt to offer patients less-invasive alterna-
tives to the surgical correction of mitral valve regurgitation.
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The Journal of Thoracic and Cardiovascular Surgeffectively correct most of the mitral valve pathologies and
ensure long-term durability, that is, leaflet repair, chordo-
plasty, and partial or full ring reduction annuloplasty. Mitral
valved stent implantation has the potential to achieve post-
procedural results similar to those of surgical repair or
replacement. We recently reported successful off-pump
transapical mitral valved stent implantation in an acute
experimental setting.2,3 The current study was designed to
assess short-term survival after transcatheter mitral valve
replacement using a similar approach.MATERIALS AND METHODS
Description of the Valved Stent
The new valved stent has 3 components: (1) an atrial fixation system con-
sisting of ultrathin high-density polyester covered metal springs (diameter
35–48 mm); (2) a ventricular body made of a nitinol self-expanding stent
frame (Nitinol Devices & Components, Fremont, Calif) that accommodates
a bioprosthetic heart valve (diameter, 25–32 mm); and (3) a ventricular fix-
ation system composed of tethering strings (cords) attached to the body of
the stent (Figure 1) and designed to be anchored to the ventricular wall.
Six glutaraldehyde-preserved aortic valves and 2 trileaflet pericardial valves
with expanded diameter ranging from 20 to 31 mm were sutured inside the
mitral stents implanted in this experiment. The folded valved stents were 11
to 13 mm wide and 28 to 34 mm long.
Description of the Procedure
Eight Yorkshire pigs, weighing between 41 and 53 kg, underwent trans-
apical off-pump valved stent implantation with a newly designed valved
stent. A lower mini-sternotomy was performed under general anesthesia,
electrocardiogram, and invasive blood pressure monitoring. The skin was
incised 6 to 8 cm over the distal sternum. The xiphoid process was removed,ery c August 2010
FIGURE 1. A, Ventricular fixation system (ie, tethering cords). B, Proto-
type valved stent partially loaded onto the deploying catheter.
Abbreviations and Acronyms
LVOT ¼ left ventricular outflow tract
TEE ¼ transesophageal echocardiography
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pericardiumwas opened, and a well was created by suturing the cut edges of
the pericardium to the skin. Two rows of 3-0 polypropylene pledgeted felt
pursestring sutures were placed around the left ventricular apex creating an
area exposed for transcatheter access of 3 to 4 cm in diameter. A heparin bo-
lus of 4000 IU was administered intravenously. Transesophageal echocardi-
ography (TEE) was performed, and midesophageal 4-chamber, 2-chamber,
and long-axis views were used to measure the maximal diameter of the mi-
tral valve annulus. TEE was subsequently used to position the delivery sys-
tem and guide the deployment of the new valved stent across the mitral
valve. The valved stents were unloaded from a custom front-loading deliv-
ery system illustrated previously2,3 using a 2-stage procedure. The left
ventricular long axis was brought into view by TEE at a 0-degree angle,
and the atrial component of the stent was then partially deployed. The posi-
tion of the delivery system was then adjusted to ensure the atrial fixation
springs of the valved stent lie above the mitral valve annulus. A 140-degree
angle view was used for the subsequent valved stent positioning. The
remaining part of the stent was deployed by retracting the delivery sheath
and visualizing the left ventricular long axis with the TEE at a 140-degree
angle. Because the Doppler left ventricular outflow tract (LVOT) interroga-
tion cannot be performed from a transgastric position in the swinemodel, we
used the angle correct feature of the Doppler packet to compensate for the
axis variation in the mid-esophageal long-axis plane for the estimation of
LVOT gradients (Table E1). The delivery sheath was removed, and the an-
choring chords were affixed to the myocardium and adjusted to ensure the
least paravalvular leak during each experiment. A full TEE examination of
the mitral valved stent was performed, including color, pulse-wave, and
continuous-wave Doppler assessment of mitral valve inflow and LVOT.
A direct contrast left ventriculogram completed the valved stent assessment
before the chest closure. A number 10 Jackson Pratt drain (Medex Inc, Dub-
lin, Ohio) was left in the pericardial cavity and attached outside to its porta-
ble drainage reservoir. Animals were allowed to recover from anesthesia,
had the arterial and venous lines removed, and were subsequently extu-
bated. Animals were then continuously monitored noninvasively for signs
of distress for an additional 6 hours, at the end of which they were reintu-
bated and underwent a second TEE examination under general anesthesia.
Subsequently, the animals were quickly extubated and allowed to fully re-
cover. They were then given postoperative oral antibiotics for 48 hours and
aspirin daily for the duration of the experiment. Animals were assessed sev-
eral times daily, and those that showed signs of distress were euthanized.
A TEE examination under general anesthesia was planned for 1 week after
mitral valved stent implantation. Necropsy was performed in all animals.
Experiments were carried out, and animals were cared for at the Experimen-
tal Surgery Unit at the University of Wisconsin in Madison, a facility
accredited by the American Association of Laboratory Animal Care. All
animals receive humane care in compliance with the ‘‘Principles of Labora-
tory Animals,’’ formulated by the National Society of Medical Research,
and the ‘‘Guide for the Care and Use of Laboratory Animals,’’ prepared
by the Institute of Laboratory Animal Resources and published by the
National Institutes of Health (publication 85-23, revised 1985). The study
protocol was approved by the University of Wisconsin Research Animal
Resource Center.
RESULTS
No valved stent migration or embolization was seen in
any of the animals. Atrial and ventricular ectopic beatsThe Journal of Thoracic and Caoccurred during preparation of apical access and during
valve deployment in all animals. No sustained or hemody-
namically relevant arrhythmias were recorded. The mean
native mitral valve annular diameter was 24.6  1.4 mm,
ranging from 22 to 27 mm (Table 1). The mean mitral valved
stent size was 26  2.6 mm, ranging from 23 to 29 mm. All
but 3 valved stents were larger than the measured mitral
valved annulus (Table 1).
The mitral valved stent was deployed successfully in all
animals. There were between 1 and 3 attempts to adequately
position and deploy the valved stent across the mitral valve
annulus. If maldeployment was recognized at the time of
implantation or the amount of mitral regurgitation was
more than mild, the valved stent was retrieved, reloaded
onto the delivery catheter, and redeployed. The average
deployment time was 3.4  1.8 minutes, and the blood
loss averaged 268  131 mL. The average mean gradients
across the native mitral valve and through the newly
deployed mitral valved stent were nearly identical, 2.0 ver-
sus 1.8 mm Hg (Table E1). The average gradient through
the valved stent increased after 6 hours and at 1 week, but
it remained clinically and hemodynamically insignificant
(Table E1). No systolic anterior motion of the anterior mitralrdiovascular Surgery c Volume 140, Number 2 423
TABLE 1. Procedural data
Animal
MV
annulus
(mm)
MV stent
(mm)
No.
Attempts
Deployment
time
(min)
Blood loss
(mL)
1 22 27 2 3 310
2 25 23 1 3 160
3 27 29 3 2 380
4 25 23 3 5 400
5 25 29 1 1 70
6 25 27 1 7 420
7 24 27 1 3 150
8 24 23 1 3 257
Mean 24.6 26.0 1.6 3.4 268
MV, Mitral valve.
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mean gradient across the neighboring LVOT did not change
after deployment of the mitral valve stent (Table E1). For
a representative color flow TEE examination showing unob-
structed LVOT flow and no systolic anterior motion, see the
supplementary online video. Left ventriculography was per-
formed through the apical access and before its closure to
confirm the TEE findings in all animals. A representative
left ventriculogram is provided as a supplementary online
video.
Animals survived an average of 7.3 days after mitral
valved stent implantation (Table 2). According to the nec-
ropsy findings, animals were retrospectively grouped in early
and late groups (n¼ 4 each). Animals that died before 1week
(early group) survived an average of 25 hours (range, 8–42
hours) and were found at necropsy to have valved stent mal-
deployment at the atrial level (Figure 2). Animals that sur-
vived more than 1 week (late group) were alive for an
average of 13.5 days (range, 7–29 days). The causes of death
were failure of atrial fixation system (ie, fracture of the nitinol
springs) in 2 of 4 animals (Figure 3), failure of ventricular fix-
ation system in 1 animal, and pseudomonas bioprosthetic en-
docarditis in the remaining animal. None of the valved stents
had any nitinol stent fractures in the ventricular body of the
stent that accommodated the bioprosthesis.TABLE 2. Outcome data
Animal
Mitral regurgitation
6 h 1 wk Survived
Failure
mechanismPost-deployment
1 Mild Mild 42 h Maldeployment
2 Trace Trace 30 h Maldeployment
3 Mild Severe 8 h Maldeployment
4 Mild Mild 20 h Maldeployment
5 Trace Mild Mild 29 d Ventricular
fixation
6 Trace Trace Moderate 7 d Endocarditis
7 Trace Trace Trace 11 d Atrial fixation
8 Trace Trace Mild 7 d Atrial fixation
Mean 7.3 d
424 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
Transcatheter replacement of atrioventricular heart valves
remains the most challenging area of transcatheter valve
therapy. Although both aortic and pulmonary valved stent
implantations are currently being considered as alternatives
to high-risk surgical treatment, transcatheter mitral or tricus-
pid valve replacement has only been proven as a concept in
an acute experimental setting.4 Current aortic and pulmo-
nary valved stent designs use the same principles and mech-
anisms of anchorage of present endovascular stents, that is,
stent oversizing and use of radial force. This is because the
aortic and pulmonary valved stents are secured mostly in
an intravascular position. In fact, the intracardiac portion
of these valved stents is responsible for many of the postim-
plantation complications, such as third-degree heart block
requiring pacemaker implantation, which occurs in up to
20% of patients with 1 aortic valved stent,5 and stent frac-
tures, seen up to 21% in patients implanted a pulmonary
valved stent.6 However, the use of radial force for anchoring
a mitral valved stent was recently reported with success in
a ‘‘valve-in-a-valve’’ model.7 This concept of implanting
a mitral valved stent inside a surgically placed bioprosthesis
has been applied in clinical practice.8 Nevertheless, the use
of radial force to anchor a valved stent across a ‘‘native’’
atrioventricular valve not only produces an acute distortion
of the neighboring structures but also promotes progressive
dilation of its dynamic and muscular atrioventricular annu-
lus.2,3 Ma and associates4 noted a few of these implantation
hurdles in their first report of mitral valved stent implanta-
tion in an acute series of experiments. They reported
successful valve stent functioning in 8 pigs for a period of
30 minutes, after which stent migration and embolization
led to demise of all animals within 180 minutes. Inadequate
valved stent anchoring results in both paravalvular leakage
and stent embolization. Boudjemline and colleagues9
reported animal survival up to 1 month after tricuspid valve
stent implantation in 4 ewes that did not experienced device
embolization. Mitral valved stent implantation carries the
highest embolization risk because the valved stent is not
only under the stress of cyclical compressions of the muscu-
lar part of the annulus but also bears a higher pressure gradi-
ent for its valve closure than any other cardiac valve. We
thus created a ventricular fixation system represented by
valved stent tethering cords to counteract the retrograde dis-
placement force created during valved stent closure and ven-
tricular systole. The axial anchorage created by atrial and
ventricular fixation systems allows for unobstructed LVOT
flow and reduced compression stress from the cyclic annular
contractions. This anchorage system allowed us to use
valved stents of different ventricular frame diameters. We
learned from our pilot experiments that we do not need to
match the diameter of ventricular frame to the size of native
mitral valve annulus. Therefore, the valve sizes and theirery c August 2010
FIGURE 2. Early failure mechanism: atrial maldeployment. A, Postmortem examination of left atrium showing 1 atrial spring caught underneath the anterior
leaflet of the mitral valve. B, Correct deployment.
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difference between the ventricular frame size and the mitral
annulus remains less than 10 mm. Three of 8 animals were
implanted with valved stents of smaller body diameter
than the size of the native mitral annulus (Table 1, animals
2, 4, 8). Because the ventricular frames of the valve stents
were only a few millimeters larger than the mitral annulus
in 5 of 8 animals and smaller in 3 of 8 animals, no nitinol
fractures were seen in the ventricular portion of the stent
that carries the bioprosthesis.
Animal survival ranged from 8 hours to 29 days. Three of
8 animals had mild paravalvular regurgitation immediately
after deployment. Six hours later, 1 more animal developed
mild paravalvular regurgitation and 1 animal with initial
mild paravalvular regurgitation developed severe mitral re-
gurgitation. All 4 animals died within 42 hours. Necropsy re-
vealed that these animals had maldeployment of the atrial
fixation system at the time of implantation (Table 2,
Figure 2). We believe this complication could have been
avoided by better integration of TEE and fluoroscopy find-
ings during valved stent deployment.
Half of the animals survived 1 week or more. Necropsy
revealed that all but 1 animal, which died of pseudomonasFIGURE 3. Late failure mechanism: failure of the atrial anchoring system. A, I
Ex vivo illustration of stent fracture (arrow).
The Journal of Thoracic and Caendocarditis, had structural stent failure, that is, breakage
of atrial and ventricular fixations (Table 2, Figure 3). The
handmade valved stents created for this study were meant
to prove the concept of the new fixation system and not to
test its durability. We were content to note the animals could
carry out their normal activities for a few weeks after mitral
valved stent implantation. Three-dimensional imaging of
valved stent positioning along with computational models,
such as finite element analysis of the valved stent compo-
nents, could identify the high stress areas that need to be tai-
lored for enhanced durability. This task is nevertheless
complex considering the interactions of the valved stent
with the mitral valve environment is complex because of
the heterogeneous material composition, dynamic geometric
layout, and variable loading conditions.
The transapical approach provided close proximity access
to themitral valve. However, we found that the retrograde ac-
cess from the higher pressure left ventricular chamber to the
lower pressure left atrium was at times difficult. The added
complexity of navigating the stent delivery system between
intact mitral valve chordae on the beating heart makes the
crossing of the mitral valve more challenging than the cross-
ing the aortic valve through a similar transapical approach.n vivo illustration of stent fractures at the highest stress points (arrows). B,
rdiovascular Surgery c Volume 140, Number 2 425
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tem may facilitate implantation of a similar mitral valved
stent design through a transseptal antegrade approach.
Study Limitations
One study limitation is that the swine model does not
allow direct Doppler interrogation of the LVOT from a trans-
gastric position. The angle-correct feature was used to cor-
rect for the off-axis Doppler interrogation of the LVOT
from the mid-esophageal position to approximate the
LVOT gradients and velocities before and after the implan-
tation.
The study also focused on testing the short-term perfor-
mance of the new valved stent anchorage system that al-
lowed animal survival after implantation. Durability of this
type of valved stent and the long-term effects on myocardial
performance of its axial anchorage system are unknown.
CONCLUSIONS
Achievement of secure and reliable anchoring is an essen-
tial step for intracardiac valved stent implantation. Short-term
animal survival was possible by achievement of effective
mitral valved stent function and anchoring. No valved stent
embolization was seen in any of the animals in this study or
our prior studies. Further refinements in the stent construction
and design will be tested to assess its durability.426 The Journal of Thoracic and Cardiovascular SurgThe authors thank Christine Hass and Marion Frahm for help
with the valved stent construction, Annette Fisher for assistance
with animals’ comparative pathology, Kim Maurer and Dan Co-
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TABLE E1. Echocardiographic data (mm Hg)
Mitral valve gradient (mean) LVOT gradient (mean)
Animal Before deployment Postdeployment 6 hrs 1 week Before deployment Postdeployment 6 hrs 1 week
1 1.0 1.3 3.1 1.3 1.2 1.7
2 1.4 0.8 1.4 1.2 1.1 1.1
3 3.5 3.7 2.9 2.4 0.3 0.2
4 3.0 1.0 1.7 1.7 1 1.7
5 1.2 2.5 6.6 4.3 1.5 0.8 0.4 2.3
6 1.9 2.8 3.9 5.3 2.7 4.6 1.7 1.3
7 1.1 1.3 4.8 0.9 0.9 0.3 1.7 1.3
8 3.1 1.1 2.4 6.3 2.4 1.4 2.3 2.5
Average 2.0 1.8 3.4 4.2 1.8 1.3 1.4 1.9
LVOT, left ventricular outflow tract.
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